MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Drug-induced parkinsonism(DIP)"

  • 2017 International Congress

    Tacrolimus induced parkinsonism presenting as freezing of gait and speech

    V. Paramanandam, H. DS, P.C. N (Chennai, India)

    Objective: Tacrolimus a calcineurin inhibitor is the most widely used immunosuppressant in post transplant patients. Mild adverse effects like tremors and parasthesia and occasionally major…
  • 2017 International Congress

    All-trans-retinoic Acid pretreatment exhibits neuroprotective effect against 6-hydroxydopamine-induced hemi-parkinsonian rats

    A. Morad Ganjeh (Karaj, Islamic Republic of Iran)

    Objective: This study examined the effect of pretreatment with All-trans-retinoic Acid (ATRA) on the 6-hydroxydopamine-induced Parkinsonism in Wistar rats in order to find out whether…
  • 2017 International Congress

    Corticobasal syndrome due to brain tumor

    P. Tsitsi, G. Xiromerisiou, T. Kalantzakou, T. Bourinaris, G. Deretzi (Stockholm, Sweden)

    Objective: To describe a case of a 60-year-old female that presented with cognitive decline and gait disorders for the last 7 years.   Background: The…
  • 2017 International Congress

    The Use of Atypical Antipsychotics in Depression and Anxiety may Unmask Parkinson’s Disease: A Retrospective Chart Review

    K. Amodeo, R. Schneider, I. Richard (Rochester, NY, USA)

    Objective: Characterize the population with parkinsonism and exposure to antipsychotics who underwent dopamine transporter single-photon emission computed tomography (DATSPECT). Background: Atypical antipsychotics are used in …
  • 2017 International Congress

    Utility of DaTscan Imaging in Differentiating Drug Induced Parkinsonism from IPD and Other Forms of Parkinsonism

    M. Salgado, D. Panebianco, J. Muller, A. Ortega, S. (Brooklyn, NY, USA)

    Objective: To determine clinical correlates which differentiate drug induced Parkinsonism (DIP) from IPD and other forms of Parkinsonism using DaT-SPECT imaging. Background: DaT-SPECT imaging is…
  • 2017 International Congress

    Is Hypertension and Certain Anti Hypertensive Agents Increase The Risk of Parkinson Disease?

    R. Pinzon (Yogyakarta, Indonesia)

    Objective: The aim of this study is measure the risk of PD related to hypertension and certain use of anti hypertensive treatment.   Background: Cardiovascular risk…
  • 2017 International Congress

    Transcranial sonography in the prognosis of drug-induced parkinsonism

    Y.-S. Oh, D.-Y. Kwon (Seoul, Republic of Korea)

    Objective: We investigated the substantia nigra (SN) echogenicity in drug-induced parkinsonism (DIP), Parkinson's disease (PD), and healthy controls. A subgroup analysis of DIP by clinical…
  • 2016 International Congress

    Neuronal nicotinamide-N-methyltransferase (NNMT) in Parkinson’s disease

    K. Schmeisser, A. Parker (Montreal, QC, Canada)

    Objective: Understanding the role of NNMT in initiation and progression of Parkinson's disease (PD). Background: 10-15% of all PD cases are caused by genetic factors,…
  • 2016 International Congress

    Risk of movement disorders with antipsychotic drugs in patients with schizophrenia or depressive disorders

    M.V. Rey, L. Molina, B. Recinos, B. Paz, M. Rovelo, F.E. Rodriguez Elias, J. Calderon, A. Arellano, S. Pomata, S. Perez-Lloret, CA-APD Study Team (Buenos Aires, Argentina)

    Objective: To compare the risk of movement disorders with antipsychotic drugs (APDs) in patients suffering from Schizophrenia or Depressive Disorders. Background: APDs are well-known causes…
  • 2016 International Congress

    Frequency of echogenic abnormality of the substantia nigra is increased in methamphetamine users

    J.J. Rumpf, J. Albers, C. Fricke, D. Weise, J. Classen (Leipzig, Germany)

    Objective: To investigate structural abnormality of the substantia nigra (SN) in methamphetamine users using transcranial sonography (TCS). Background: Epidemiologic studies suggest that chronic use of…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley